Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Avastin

Avastin is a medicine containing the active ingredient(s) bevacizumab. On this page you will find out more about Avastin, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: bevacizumab

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Avastin 100 mg/4 mL concentrated injection, 4 mL vial

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Metastatic ColorectaI Cancer AVASTIN (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer. Locally recurrent or metastatic Breast Cancer AVASTIN (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated.(see Clinical Trials). Advanced, metastatic or recurrent non-squamous Non-Small Cell Lung Cancer (NSCLC) AVASTIN (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous non-small cell lung cancer. Advanced and/or metastatic RenaI Cell Cancer AVASTIN (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer Grade IV Glioma AVASTIN (bevacizumab) as a single agent, is indicated for the treatment of patients with Grade IV glioma after relapse or disease progression after standard therapy, including chemotherapy. EpitheliaI Ovarian, Fallopian Tube or Primary Peritoneal Cancer AVASTIN (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (FIGO stages IIIB, IIIC and IV) epithelial, ovarian,fallopian tube, or primary peritoneal cancer. Recurent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer AVASTIN (bevacizumab), in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other VEGF-targeted angiogenesis inhibitors. AVASTIN (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti-angiogenic therapy including bevacizumab. Cervical Cancer AVASTIN (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. AVASTIN (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance Clear to slightly opalescent, colourless to pale brown solution.
Dosage Form Injection, concentrated
Route of administration Intravenous
Medicine schedule
1 Vial: Prescription Only Medicine, or Prescription Animal Remedy

There is one type of pack available.

Pack type 1
Pack type 1
Type Vial
Storage temperature Store at 2 to 8 degrees Celsius
Storage conditions Refrigerate,Protect from Light,Do not Freeze
Life time 2 Years
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 7 results

Avastin Concentrate for intravenous infusion - myDr.com.au

Avastin Concentrate for intravenous infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Avastin (bevacizumab(rch)) information | myVMC

Avastin (bevacizumab(rch)) is used to treat brain tumours and metastatic cancer of the large bowel, breast, lung, kidney and cervix with chemotherapy.

Read more on myVMC – Virtual Medical Centre website

Roferon-A (interferon alfa-2a (rbe)) information | myVMC

Roferon-A (interferon alfa-2a (rbe)) is used in the treatment of chronic active hepatitis B and chronic hepatitis C and various types of cancer.

Read more on myVMC – Virtual Medical Centre website

Roferon-A Injection - myDr.com.au

Roferon-A Injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Diabetic Macular Oedema | myVMC

Diabetic macular oedema is a sight-threatening eye condition

Read more on myVMC – Virtual Medical Centre website

Biological Therapy (Biotherapy) | myVMC

Biological therapy, or biotherapy, immunotherapy or biological response modifiers, are gaining increasing prominence as anti-cancer agents. They may be used either alone or in combination with traditional anti-cancer treatments such as chemotherapy.

Read more on myVMC – Virtual Medical Centre website

Macular Degeneration | myVMC

Macular degeneration affects the nerves in the macula, the central portion of the eye's retina. It affects high acuity vision needed for sharp focus.

Read more on myVMC – Virtual Medical Centre website

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo
Feedback